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In  the  past  the complement  (C) 1 system  has  been  primarily characterized as the 
plasma cytotoxic effector mechanism  of the immune  response that  complements the 
recognition  function  provided  by  specific  antibody.  Although  this  description  is 
certainly applicable to the classical pathway of C  activation, it is now recognized that 
the alternative pathway usually is not activated directly by immune complexes and 
has  its own  antibody-independent  mechanism  for recognition of non-self structures 
(1).  With  the  finding  of  lymphocyte  and  macrophage  synthesis  of  most  of  the 
components, inhibitors, and regulatory proteins of both the alternative and classical 
pathways of C  activation  (2-5),  the question  arises as to whether  these components 
constitute a  cell-bound system that is functionally analogous to the plasma C  system, 
particularly with regard to the recognition of alternative pathway-activating surfaces. 
Initiation of the alternative pathway involves the spontaneous activation of C3  (6) 
that binds randomly as C3b to nearby surface carbohydrate structures  (7). Unbound 
C3b or C3b bound  to normal tissue is rapidly cleaved into C3bi by C3b inactivator 
(C3bINA), whereas C3b bound to an activating surface resists C3bINA cleavage and 
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i Abbreviations used in this paper: fllH or/~IH globulin, essential cofactor for cleavage of fluid-phase C3b 
by C3b inactivator (11), and a potentiator of C3b inactivator cleavage of bound C3b (12); Bb, activated 
factor B; C, complement;  BSA, bovine serum albumin; BDV, BSA dextrose veronal buffer; BDVA, BDV 
with 0.2% sodium azide; BDVE, BDV with 20 mM EDTA; C3b,  180,000-dahon fragment of C3; C3bi, 
C3b inactivator cleaved C3b; C3c, 140,000-dahon fragment ofC3bi; C3d, 30,000-dahon fragment of C3bi 
that remains bound to surfaces after proteolysis of C3bi; C3bINA, C3b inactivator;  CRy, C receptor type 
one, the C4b-C3b receptor; CR2, C receptor type two, the C3d-C3bi receptor; CRy, C receptor type three, 
the C3bi receptor; E, erythrocyte; EA, IgM-antibody-sensitized E; EC3, sheep E coated with C3; EAC, EA 
coated with  C;  EACA, epsilon amino caproic  acid;  EDTA-DGVB,  20 mM EDTA  in dextrose gelatin 
veronal buffer; FITC, fluorescein isothiocyanate; GVB, gelatin veronal buffer; Mg-BDV, BDV containing 
10 mM magnesium chloride and 10 mM EGTA; NF, nephritic factor, human IgG antibody specific for the 
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glycol; PBS, phosphate-buffered  saline; PBS-BSA, PBS containing  1% BSA and 0.2% sodium azide; SDS, 
sodium dodecyl sulfate;  SDS-PAGE, SDS-polyacrylamide  gel electrophoresis; TRITC, tetramethyl  rho- 
damine isothiocyanate. 
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instead  combines  with  activated  factor  B  (Bb)  and  properdin  (P)  to  form  the 
amplification convertase  (C3b,Bb,P).  This  surface-bound  C3b,Bb,P  rapidly cleaves 
more C3,  generating a  bound cluster of C3b that binds C5  and makes it susceptible 
to cleavage-activation by the C3b,Bb,P.  Activated C5  (C5b) then combines with C6, 
C7, C8, and C9 to form the cytotoxic membrane attack complex./~IH globulin (,B1H) 
has the recognition function that  directs C3blNA to either unbound  C3b or to C3b 
bound to normal tissue, thus preventing total consumption of plasma C  and protecting 
normal tissue from cytolysis (8-11). 
In our study, B lymphocytes were found to have membrane receptors for/31H. The 
binding of/~IH  to  these  receptors was  shown  to  induce  the  release of endogenous 
C3blNA from lymphocytes, resulting in cleavage of EC3b into EC3bi. These resultant 
EC3bi then bound to B cell C  receptor type two (CR2, the C3d receptor) and did not 
bind  to  C  receptor type one  (CR1,  the  C3b-C4b  receptor).  B  cell-derived C3blNA 
thus produced CR2-dependent rosette formation with EC3b. 
Materials  and  Methods 
Cell Isolation and  Culture.  Normal  blood and  tonsil  lymphocytes were  isolated on  Ficoll- 
Hypaque as previously described (12) and then monocytes were removed by absorption onto 
Sephadex  G-10  (Pharmacia  Fine  Chemicals)  (13).  B  lymphocyte-enriched  fractions  were 
prepared by depletion ofT lymphocytes forming rosettes with sheep E (14). More than 75% of 
the  cells in  the  tonsil  B  cell fraction  were  stained with  F(ab')2 anti-immunoglobulin  (Ig)- 
tetramethyl-rhodamine isothiocyanate (TRITC).  The  Burkitt's lymphoma-derived lympho- 
blastoid cell lines known  as Raji and  Daudi,  and  the  B.  F.  line derived from  transformed 
normal lymphocytes (kindly provided by Dr. James Simmons, University of North Carolina at 
Chapel Hill, N. C.), were maintained in RPMI-1640 media supplemented with  10% fetal calf 
serum, penicillin, and streptomycin. 
Purified C Components and Enzymes.  Plasminogen, C4, C2, C3, C5, factor B, ~ 1  H, and C3bINA 
were isolated from a single 3-liter pool of fresh citrated plasma. Plasminogen was isolated from 
protease inhibitor-treated plasma by  affinity chromatography on  lysine-agarose (15).  After 
precipitation of fibrinogen by addition of 5  g solid polyethylene glycol 4000  (PEG)  (Sigma 
Chemical Co., St. Louis, Mo.) per 100 ml plasma, the plasma was diluted to 2 mS conductivity 
(4°C) with 5 mM Tris/HCl, pH 7.8, that contained 50 mM epsilon amino caproic acid (EACA) 
(Sigma Chemical Co.), 5 mM  EDTA,  10 mM benzamidine (Sigma Chemical Co.), and 0.5 
mM phenylmethylsulfonyl fluoride (Sigma Chemical Co.). After concentration to 3 liters with 
a  Millipore Pellicon concentrator with  5  square  feet of PSED  membrane  (Millipore Corp., 
Bedford,  Mass.),  the  sample was  loaded onto  a  10-  ×  120-era  column  of DEAE-Sephacel 
(Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) equilibrated with  10 
mM Tris/HC! pH 7.8, conductivity 2 mS (4°C), that contained 50 mM EACA, 5 mM EDTA, 
and  10 mM benzamidine. After a  12-liter wash with starting buffer, the column was eluted 
with a  30-liter linear NaCI gradient progressing to 0.3  M  NaCI. C3bINA eluted at  2.7  mS 
conductivity (4°C), C2 at 3.4 mS, factor B at 4.0 mS,/31H at 5.2 mS, C5 at 6.2 mS, C3 at 8.0 
mS, and C4 at 10.6 mS. 
One pool that contained C3bINA and one-half the C2, and a second pool that contained 
factor B and the remaining C2, were each adjusted to pH 7.0 with 1 N HCI, diluted to 1.3 mS 
(4°C)  with veronal buffer, pH  7.0,  and loaded onto two 4- ×  60-cm columns of Bio-Rex 70 
(Bio-Rad  Laboratories, Inc.,  Richmond,  Calif.)  equilibrated  with  veronal  buffer,  pH  7.0, 
conductivity 1.3 mS (4°C), containing 50 mM EACA and 5 mM EDTA. After a  1.5-liter wash 
with this buffer, each column was eluted with a 3 liter linear NaCI gradient progressing to 0.3 
M  NaCI. The three separate activity peaks of C3bINA, C2, and factor B that eluted at 1.6 mS, 
9.2 mS, and  14.6 mS respectively, were each concentrated to  15 ml with a  PM-10 membrane 
(Amicon Corp., Scientific Systems Div., Lexington, Mass.) and chromatographed on a 5- ×  90- 
cm column of Sephadex G-150 equilibrated with 100 mM phosphate buffer, pH 7.4, containing 
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then chromatographed on a 2- ×  30-cm column of C3b-agarose containing 3 mg of cyanogen 
bromide-linked C3b (16, 17)/ml of gel. C3bINA bound to C3b-agarose in 30 mM NaC1, 5 mM 
phosphate pH 7.0, and was eluted with PBS. Factor B bound to C3b-agarose in 10 mM MgCI2 
in veronal buffer, pH  7.2, and was eluted with  10  mM  EDTA in veronal buffered saline. 
Common contaminants of the C3bINA, factor B, and C2 were then removed by immunoab- 
sorption with agarose linked antibodies specific for fllH, C3, albumin, transferrin, hemopexin, 
IgG, and IgA. 
The fllH, C5,  C3,  and C4 each  eluted  in distinct activity peaks  from  DEAE-Sephacel, 
making subsequent hydroxylapatite chromatography unnecessary (15). Each was precipitated 
from column fractions by addition of solid PEG to 16% (wt:vol), redissolved in 40-60 ml of 100 
mM sodium phosphate buffer pH 7.4 containing 150 mM NaCI, 50 mM EACA, 5 mM EDTA, 
and 0.2% sodium azide, and chromatographed on a  10- ×  120-cm column of Sepharose CL-6B 
equilibrated in the same buffer. The fllH was then immunoabsorbed with agarose conjugated 
to IgG antibodies specific for IgA, IgG, C3, C5, a2-macroglobulin,  and C3bINA. The fllH was 
homogenous by both sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(18) and no contaminants were detected by immunodiffusion  analysis over a dilution range of 
20 mg/mi to 50 #g/ml with a  variety of different antisera. The purified fllH did not cleave 
fluid-phase C3b at a  1:1 (wt:wt) ratio after 20 h at 37°C. By comparison, C3b was completely 
cleaved to C3bi after 20 h at 37°C by a mixture of 0.5% fllH and 0.2% C3bINA (wt:wt). The 
C4 was further purified by chromatography on QAE-Sephadex (Pharmacia Fine Chemicals) 
and DEAE Bio-Gel A (Bio-Rad Laboratories, Inc.) as described by Bolotin et al (19). Both the 
C3 and C5 were immunoabsorbed with agarose conjugated to antibodies specific for IgG, IgA, 
and fllH, after which the C3 was absorbed with agarose-anti-C5, and the C5 was absorbed 
with agarose-anti-C3. The C4, C3, and C5 were each judged to be >95% pure by SDS-PAGE 
and immunodiffusion analysis with a variety of antisera over a dilution range of 20 mg/ml to 
50 #g/ml. 
C3 nephritic factor (NF) was partially purified (20) from the plasma of a patient with partial 
lipodistrophy (kindly provided by Dr.  W.  Ray Gammon, University of North  Carolina at 
Chapel Hill). Functionally  pure factor I~ was isolated from 20 ml of twofold concentrated (PM- 
10 membrane) whole serum by chromatography on a 5- × 90-cm column of Sephadex G-75 in 
veronal-buffered saline. 
Antibodies  to  C  Components and  C  Receptors.  Rabbits were  immunized with  C3c  and C3d 
fragments prepared by trypsin cleavage of purified C3 (16). In immunodiffusion  tests, anti-C3c 
formed a precipitin line of identity with C3, C3b, and C3c, but was unreactive with C3a, C3d, 
or flirt. Anti-C3c had an agglutinating titer of 2,400 with either EC3b or EC3bi (1 ×  108/ml), 
but did not agglutinate EC3d. Anti-C3d formed a precipitin line of identity with C3, C3b, and 
C3d, but formed no line with C3c, flirt, or C3a. Anti-C3d had an agglutinating titer of 400 
with either EC3b or EC3bi, and a titer of 800 with EC3d. Fab fragments of these two antibodies 
were isolated by papain cleavage and chromatography on CM-52 cellulose (Whatman Chem- 
icals, Division of W and R Balston, Maidstone, Kent, England) (21). Two different goat anti- 
C3bINA sera were used. One was a  gift  from Dr.  Robert  D.  Schreiber, Scripps Clinic and 
Research  Foundation, La Jolla,  Calif., and  the  other was  a  girl  from  Dr.  Brian F.  Tack, 
Harvard Medical School, Boston, Mass., that was produced by immunization  with the purified 
C3bINA described  in the  preceding section.  When tested  by  immunodiffusion, both  anti- 
C3bINA sera formed a single precipitin line of identity between purified C3bINA and whole 
human serum, and were unreactive with various dilutions of purified C3, IgG, flirt, factor B, 
and P. The IgG fraction of one anti-C3bINA serum was isolated by chromatography on DEAE- 
Sephacel in 0.02 M Tris/HC1 pH 8.0, and after concentration to 34 mg/ml, was shown to be 
free of goat C3bINA activity. Goat anti-fllH was a gift  from Dr. Brian F. Tack produced by 
immunization with  the  purified fllH  described above.  F(ab')2 fragments of anti-fllH were 
produced by trypsin cleavage of DEAE-isolated IgG (22), followed by column chromatography 
on Sephadex G- 150. 
CR1  was  isolated from  1 ×  1014 erythrocyte membranes by modification of a  technique, 
originally described by Fearon  (23),  that  will be described  in more detail elsewhere  (N. J. 
Dobson, J. D. Lambris, and G. D. Ross. Manuscript in preparation.). Anti-CR1 was produced 
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adjuvant and had the same specificity as that described by Fearon (24). CR2 was isolated from 
15  liters  of  Raji  cell  culture supernate  by  ammonium sulfate  precipitation,  followed  by 
sequential steps  of column chromatography on DEAE-Sephacel, Sephadex G-150, and C3d- 
agarose. 2 Anti-CR2 was produced by weekly intramuscular immunization of rabbits with 100 
pg of pure CR2  emulsified in complete Freund's adjuvant. Anti-CR2 immunoprecipitated a 
single membrane glycoprotein of 72,000 mol wt from Nonidet P-40 (Particle Data Laboratories, 
Inc., Elmhurst, Ill.) solubilized B lymphoblastoid lines grown in a combination of 14C- and SnS- 
labeled amino acids.  F(ab')2 fragments of anti-CRl and anti-CR2 were  prepared  by pepsin 
digestion and chromatography on  Sephadex  G-150  (25). Monovalent Fab' fragments were 
produced from F(ab')~ fragments by mild reduction with 0.1 M cysteine (26). 
Labeling of Proteins with 3H,  I~I, Fluorescein, or TRITC.  Purified C3 and/~IH were  labeled 
with 3H by reductive methylation (27). For C3 this resulted in a 0.5 ×  10%2.5 ×  10  e dpm per 
pg sp act, and no detectable change in either hemolytic activity or binding site affinities for 
CR1, CR2, CR3, or ~IH. SH-labeled ~IH, 3.6 ×  l0  g dpm per p.g, had normal cofactor activity 
with C3bINA, and also normal activity in decay-dissociation of the amplification convertase 
(EC3b,Bb,P). Fab' fragments of anti-CRl were labeled with 12sI (28) and had a 6 ×  10  v cpm 
per #g sp  act.  F(ab')2 fragments of anti-CRt, anti-CRz, and anti-/~lH were each coupled to 
either fluorescein isothiocyanate (FITC) or TRITC as previously described (25). Alternatively, 
native IgG antibodies were coupled to either FITC-protein A (Pharmaeia Fine Chemicals) or 
TRITC-Protein A  (Zymed Laboratories; Burlingame, Calif.), before use for immunofluores- 
cence assay to block any possible Fc receptor interaction with the antibody. Rabbit F(ab')z 
anti-Ig-TRITC (specific for #, 8, a, and T Ig heavy chains) was prepared as previously described 
(29). 
C-coated Erythrocytes (EAC and EC).  Sheep erythrocytes (E) were coated with IgM antibody 
(Cordis Laboratories, Miami, Fla.) and purified human C components to form EAC (30). CRI- 
reactive EAC 14b were prepared with 100 pg of C4 per 1 ×  109 EACI. EC3b were prepared with 
3H-labeled C3 as described by Pangburn and Miiller-Eberhard (9), then a portion of the EC3b 
was subsequently converted to EC3bi by treatment with/31H and C3bINA, and finally some 
of the EC3bi was degraded to EC3d with  3  plasmin. For CR1 assay, 40 #g of  H-labeled C3 were 
added per 1 ×  109 EC3b,Bb,NF, resulting in a total of 1.5 ×  104-1.8 ×  104 molecules of bound 
C3b per cell  (determined by scintillation counting of solubilized cells). Such EC3b contained 
three to four times more bound C3b than was required to obtain plateau values for human E 
CRx-dependent rosette formation, and conversion to EC3bi or EC3d also resulted in plateau 
values for Daudi cell CR2-dependent rosette formation. For generation of EC3bi, EC3b at 5 
×  108/ml in 20 mM EDTA-DGVB (3.8 mS at 22°C) was mixed with an equal volume KSCN- 
treated human serum (previously dialyzed against 20 mM EDTA-DGVB) (30), and incubated 
at  37°C  for  1 h.  The presence of any residual uncleaved C3b on  EC3bi was  detected  by 
hemolytic assay for C3b sites capable of forming C3 convertase with purified factors  B and D. 
For conversion to EC3d, 5 ml of EC3bi at 5 ×  108/ml in GVB were mixed with 5 ml of freshly- 
activated plasmin (176 pg/ml) and incubated at 37°C for 30 min. Plasminogen was activated 
by mixing 2.5 ml of plasminogen at 352 pg/ml in 40 mM Tris/lysine-buffered  saline, pH 9.0, 
with  20  /zl  of urokinase at  100,000 U/ml  (kindly provided  by  Dr.  Peter  Harpel,  Cornell 
University Medical College, New York) and incubating  at 37°C for 30 min. Before addition to 
EC3bi, the pH of the plasmin was lowered to 8.0 by addition of 2,5 ml of 100 mM phosphate 
buffer, pH  7.0, in 50  mM  NaCI.  Complete cleavage of all C3bi to C3d was  confirmed by 
absence of agglutination by either anti-C3c or purified bovine conglutinin (kindly provided by 
Dr. Robert Eisenherg, University of North Carolina at Chapel Hill). 
Bovine E were also coupled to purified fllH with tannic acid (31) for assay offllH receptors 
by rosette formation. Control bovine E coupled to bovine serum albumin (BSA) were prepared 
in parallel. 
C-Receptor Assay.  Rosette assays were performed in 10- X 75-mm plastic tubes as previously 
described by mixing 100 #1 of EC or EAC at 2 ×  108/ml with  I00 #I of C-receptor cells at 4 
×  106/ml and then incubating  on a tube rotator for 15 min at 37°C (30). The assay media used 
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in all cases had a low ionic strength (6 mS conductivity at 22°C), as this was found to potentiate 
both  CRI  and CR2  activity by ~50%.  This media  (BDV)  consisted of  1%  BSA  and 3.2% 
dextrose in veronal buffer pH 7.2 with enough added NaCI to raise the conductivity to 6 mS. 
In some cases as noted, BDV was supplemented with either 20 mM EDTA (BDVE),  10 mM 
MgCI2 in 10 mM EGTA (Mg-BDV), or 0.2% NaN2 (BDVA), and then with these supplements, 
less NaCI was  added  so  that  the  final conductivity was  always 6  mS.  In experiments that 
examined the kinetics of rosette formation, samples or rosette-assay mixture were examined at 
timed intervals. 
Direct immunofluorescence of CR1  and CR2  was  performed in the same way as for other 
surface markers such as  Ig  (25). fllH receptors were detected  by immunofluorescenee after 
incubation of cells with unlabeled fllH. A pellet of 5 ×  105 cells was resuspended in 25 #1 of 
fllH at  100 #g/ml in  1%  BSA/PBS/0.2%  NaNa  (PBS-BSA)  and incubated at  37°C for  10 
minutes. Next, after only one washing step, 25 #1 of fluorochrome-anti-fllH [F(ab')2  or IgG- 
protein A] at 1 mg/ml was added to the cell pellet and incubation was continued for 20 min at 
37°C. Cells were examined for surface fluorescence after three washes in PBS-BSA. 
CRI and fl 1H receptors were also detected by radioimmune assay with ~2SI-Fab'-anti-CRi  or 
[3H]fll H, respectively. Nonspeeific uptake was assessed by measuring the uptake of radiotabeled 
ligand in the presence ofa 1,000-fold molar excess of the homologous unlabeled ligand. Graded 
amounts of [aH]fllH or  t25I-Fab'-anti-CR1  in  BDVA were  added  to  400  #1  conical plastic 
centrifuge tubes that contained 1 ×  106 cells and the total volume was adjusted to 100 btl with 
BDVA. After 30 min at 37°C, the cells were pelleted by centrifugation through oil at 8,000 g 
for 2 min (32). The floating aqueous phase was aspirated for determination of unbound ligand, 
and the cell pellet was either counted directly for 125I, or for all, solubilized with NCS Tissue 
Solubilizer (Amersham Corp., Arlington Heights, Ill.) and counted in OCS Scintillation Fluid 
(Amersham Corp.). 
Rosette Inhibition Assays.  Cell pellets of either 2 ×  10  7 EC3 or 4 ×  10  ~ C-receptor cells were 
resuspended in  100 #1  of either BDV  or  various IgG antibodies or  their F(ab')2  (or  Fab') 
fragments diluted in BDV. After 30 rain at room temperature, treated cells were either tested 
without washing, or where indicated, washed three times in BDV, and then assayed for rosette 
formation. In assays for inhibition by EDTA, Mg-EGTA, or azide, both C-receptor cells and 
EC3 were suspended in BDVE, Mg-BDV, or BDVA, respectively. 
Assay for C3blNA Synthesis.  100 ml of Raji cells at  1 ×  106/ml  were cultured for  16 h  in 
leucine-free RPMI-1640 (Grand Island Biological Co., Grand Island, N. Y.) supplemented with 
2%  fetal  calf serum, penicillin-streptomycin, and 5  mCi of [aH]teucine (Amersham Corp.). 
Alternatively, 2.2 ×  10  Raji cells were cultured in 110 ml of media supplemented with 50 #Ci 
each of 14C-labeled leucine, phenylalanine, and lysine, and 250 #Ci of [aSS]methionine.  The 
harvested cells were washed three times in PBS and solubilized with 1% Nonidet P-40 (NP-40) 
in  50  mM  Tris/HCl  pH  7.5  that  contained  100  mM  KC1. The  culture  supernate  was 
concentrated 50-fold  (PM-10 membrane), dialyzed against phosphate-buffered saline (PBS), 
and then centrifuged at 40,000 g  for  16 h.  Both solubilized cells and culture supernate were 
then mixed with an equal volume of human serum and analyzed by immunodiffusion for 
C3bINA in barbital-buffered  1%  agarose,  pH  8.6.  After 2  d  at  4°C,  soluble proteins were 
allowed to diffuse out of the agarose by immersion in 1% Triton X-100 (Sigma Chemical Co.) 
in PBS for  7 d.  Detergent and then salts were eluted by  l-d immersions in PBS followed  by 
deionized water. The agarose was dried, stained with amido black, impregnated with Enhance 
scintillant (New  England Nuclear,  Boston,  Mass.),  and  then  applied  to  X-Omat  RP  film 
(Eastman Kodak Co., Rochester, N. Y.) for 6 d at -85°C. 
The presence of C3bINA antigen was also assessed by the capacity of Raji cells to absorb 
anti-C3bINA  antibodies. A 1.0-ml pellet of washed Raji cells was lysed by freezing and thawing 
to expose  cytoplasmic components, and then fixed  in  1% glutaraldehyde-PBS for  15 min at 
37°C. After two washes with PBS-BSA and two washes with PBS,  100 gl of packed cells was 
dispensed into four  1-ml plastic conical tubes and all supernatant fluid was aspirated. Next, 
300 #1 of goat IgG anti-C3bINA at  10 mg/ml (O~80 =  14) was absorbed in succession  with 
each of the four cell pellets for 30 min at 37°C. The absorbed anti-C3bINA had an OD280 of 
10.2, indicating a  dilution of _<25%. The concentration of anti-C3bINA antibody was deter- 
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of C3bINA antigen, was  incorporated into  1%  agarose. The diameter of precipitin rings in 
dried and amido black-stained agarose were measured and the amount of anti-C3bINA was 
computed by comparison to a standard curve established with known amounts of anti-C3bINA. 
An allowance for 25% dilution was included in calculations of the amount of antibody absorbed. 
Assays for C3blNA Activity.  C3bINA activity released from flirt-treated lymphoid cells was 
measured  by two different methods:  (a)  cleavage of all-labeled C3b  on  EC3b  to  EC3bi  as 
determined by sodium dodecyl sulfate (SDS)-polyaerylamide gel electrophoresis (PAGE) and 
fluorography; (b) generation of EC3b-Raji cell rosette formation inhibitable by anti-C3bINA. 
For demonstration of EC3b  conversion to  EC3bi  by lymphoid cell C3bINA,  EC3b  that 
contained 2.5 ×  104 molecules of all-labeled C3b per cell were prepared. These EC3b[aH] at 2 
×  10a/ml  in  BDVA were mixed with an  equal  volume of flirt-induced cell supernate and 
incubated overnight at 37°C.  Controls included untreated EC3b[aH], and EC3b[aH]  treated 
with either unstimulated-cell supernate or anti-C3bINA-treated supernate from fl 1  H-triggered 
cells. After four washes with 0.15 M phosphate-buffered 0.3 M  NaCI pH 7.5, the EC3b[aH] cell 
pellet was lysed with 2% SDS, 0.1  M  dithiothreitol in 62  mM Tris/HCl, pH 6.8,  heated at 
100°C  for 5 rain, and analyzed by SDS-PAGE using 7% polyacrylamide. After staining with 
Coomassie brilliant blue and photography to record the positions of known molecular weight 
markers, the gel slab was impregnated with Enhance seintillant and applied to X-Omat RP 
film for fluorography. The film was developed after 6 d exposure at -85°C and the molecular 
weight of each radioactive band was determined from its relative mobility by reference to a 
standard curve established with the known molecular weight markers. 
C3bINA conversion of EC3b to EC3bi was also assayed by Raji cell rosette formation in the 
presence of EDTA. EDTA inhibited Raji cell C3bINA release (Results), so that Raji cell rosette 
formation in the presence of EDTA only occurred with EC3bi or EC3d. The specificity of this 
assay for C3bINA was confirmed with each different lymphoid cell type by inhibition studies 
with  anti-C3bINA. Cell-free supernates derived from  various flirt-triggered cell types were 
incubated with EC3b  for 30  min at  37°C.  Next, all fllH that  was bound to the EC3b  was 
eluted by six washing steps at 37°C with  1% BSA in 50 mM PBS  (0.25  M  NaCI), pH 7.5 (30 
mS conductivity at 22°C). Finally, the supernate-treated and washed EC3b were examined for 
Raji rosettes in BDVE. Complete removal of fll H  bound to EC3b by this washing procedure 
was confirmed in pilot studies with 3H-labeled fllH. As an additional control for possible fllH 
carryover on EC3b that might have occurred when testing supernates from flirt-treated cells, 
an equivalent amount of fllH was added to cell-free supernates derived from cells incubated 
without fllH. 
Results 
Specificity and  Sensitivity  of Assays for  C Receptors; Absence of CR1  on  Raji and  Daudi 
Cells.  Assay of lymphoid cells and erythrocytes for C  receptors by immunofluores- 
cence with CRr  and CR2-specific antibodies gave results similar to those obtained by 
conventional  rosette  assay procedures with  C-coated sheep  E  (Table  I).  The  EC3b 
rosette  assay was  the  most  sensitive for detection of CR1,  as EC3b  formed  rosettes 
with  75% of human  E  that are known to express only 900 CR1 per cell (24), whereas 
EAC14b  formed  rosettes  with  only  60%  of  human  E,  and  anti-CR1  fluorescence 
staining was undetectable on human E. The cell lines Raji and Daudi expressed CR2 
but  lacked  detectable CR1  by  both  fluorescence  and  rosette  assays.  In  addition, a 
radioimmune assay with  ~2~I-labeled-Fab'-anti-CRa was negative with these two cell 
lines. After subtraction of nonspecific uptake, human  E  bound twentyfold more lz~I- 
Fab'-anti-CRa than did either Raji cells or sheep E  (data not shown). 
The specificity of CR1  and CR2  for the C3c and C3d portions of C3,  respectively, 
was  examined  by  assays  for  inhibition  of EC3  rosette  formation  by  Fab  antibody 
fragments  specific for C3c,  C3d,  CR1,  and  CR2  (Table II),  Complete  inhibition of 
EC3b  rosette  formation  by either anti-C3c  or anti-CRx,  indicated  that  EC3b  were 
bound exclusively to CR1  at  a  binding site within the C3c region of C3b.  Anti-C3d JOHN  D.  LAMBRIS, NORMAN J.  DOBSON, AND GORDON  D.  ROSS  1631 
TASLE  I 
Assay of CRt and CR2 by C-dependent Rosette Formation Versus Direct Immunofluorescence with 
C-Receptor-spec~'c Antibodies 
CRj markers  CR2 markers 
Cell type  EAC14b  EC3b  anti-  EC3bi  EC3d  anli- 
CRI  CR2 
rosettes  rosettes  FITC  rosettes  rosettes  FITC 
% 
Erythrocytes  60  75  0  10  0  0 
Normal lymphocytes 
Blood  14  17  15  9  8  9 
Tonsils 
Unseparated  55  69  65  74  70  65 
E-rosette negative  70  90  85  92  84  81 
Lymphoblastoid celllines 
Raji  0  0  0  98  98  90 
Daudi  0  0  0  85  80  75 
B.F.  49  65  57  95  93  85 
TABLE II 
Inhibition of EC3 Rosette Formation by Antibodies Specific  for C3 Fragments and C Receptors 
EC3 type  C receptor cell  C receptor type 
Inhibition by antibody specific for 
C3c  C3d  CRI  CR2 
EC3b  Erythrocyte  CRI  100 
Tonsil B cell  CRI, CR2  100 
EC3bi  Raji or Daudi  CR~  100 
Tonsil B cell  CRt, CR2  100 
EC3d  Raji or Daudi  CR2  0 
Tonsil B cell  CRy, CR2  0 
O/tj 
0  100  0 
0  100  0 
100  0  60 
100  0  50 
100  0  100 
100  0  I00 
did not inhibit EC3b rosette formation with cells bearing both CR1 and CR2. EC3bi 
rosette formation was not inhibited by anti-CR1, indicating that EC3bi did not bind 
to CRx, despite the observation of occasional human E rosettes with EC3bi (Table I). 
Complete inhibition of EC3bi rosettes  by anti-C3d and partial  inhibition by anti- 
CR2  indicated that  at  least  some  EC3bi  were  bound to  CR2.  However,  complete 
inhibition  of EC3bi rosette formation by anti-C3c and only partial inhibition by anti- 
CR2 suggested that EC3bi might also be bound to a  third type of C  receptor (Table 
II).  EC3d were not inhibited from  forming rosettes by either anti-C3c or anti-CRl, 
whereas anti-C3d and anti-CR2 completely inhibited EC3d rosette formation with all 
cell types. 
flirt-induced EC3b Rosette Formation with CRl-Negative  Lymphoid Cells.  Even though 
EC3b  did  not  bind  to  Raji  cells,  small  amounts of  purified fllH  induced  dose- 
dependent EC3b rosette formation with Raji cells (Figure I). Kinetic studies of Raji 
cell-EC3b rosette  formation  induced by  30 gg/ml fllH,  indicated that  maximum 1632  ~IH-INDUCED  RELEASE  OF  C3b  INACTIVATOR 
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FIG.  1.  Dose-dependence  of flirt-induced  EC3b  rosette  formation  with  Raji  cells.  EC3b  was 
resuspended ir  increasing concentrations of purified ~IH  in  BDV,  and then assayed for rosette 
formation with Raji cells for 30 rain at 37°C. 
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Fic~.  2.  Kinetics of EC3 rosette formation with Raft and Daudi lymphoblastoid ceils. ECSbi rosette 
formation with Raji cells (0) and Daudi cells (11) occurred more rapidly than did/~lH-induced  (30 
#g/ml)  EC3b rosette formation with Raji cells (©) and Daudi Cells ([]). No ECSb rosette formation 
was observed in the absence of~lH  with either Raji cells (A) or Daudi cells (A). Pretreatment of 
Raji  cells with  IgG  anti-C3bINA  followed  by  two  washing steps and  resuspension with  BDV, 
reduced the rate of flirt-induced EC3b rosette formation (0). 
rosette  formation  required  45-60  min,  as  compared  to  only  2  min  for  maximum 
rosette  formation  with  EC3bi  (Fig.  2).  A  few  Daudi  cell-EC3b  rosettes  were  also 
observed after 60 min with 30/~g/ml ~IH; however, neither Daudi nor Raji formed 
rosettes with  EC3b  after 60  min  in  the absence of fllH.  Raji  and  Daudi  cells also 
formed rosettes with preformed EC3b-/~ 1H complexes prepared with 3H-labeled/~ 1H. 
Maximum  Raji cell rosette formation was achieved in  10 rain with  8.8  ×  103/~IH 
molecules bound per EC3b-fl 1H. Removal of all bound [3H]fl 1H from EC3b-fl I H  by 
six washes with high ionic strength  (30 mS conductivity at 22°C)  buffer, resulted in 
complete loss of the ability of the EC3b to form rosettes with Raji cells. 
Specificity of flirt-induced Rosette Formation.  The binding of EC3b-fllH to Raji cells 
was not  inhibited  by the incubation of Raji cells in 5.5  mg/ml offllH, both before 
and during the rosette assay with EC3b-fllH. flirt-induced  EC3b rosette formation 
was completely inhibited by the presence of anti-C3c or anti-C3d in the assay mixture, 
but little or no inhibition was observed if either Raji or EC3b were first treated with 
these same antibodies and washed before rosette assay (Table III). Studies with 3H- 
labeled fllH  indicated  that  the amounts of anti-C3c and  anti-C3d  used  for rosette JOHN D.  LAMBRIS, NORMAN J.  DOBSON, AND GORDON  D.  ROSS 
TABLE III 
Inhibition of flirt-induced Raft Cell-EC3b Rosette Formation by Antibodies 
Specific for C3 Fragments, C Receptors, and C3blNA 
Antibody  Inhibition of rosette formation 
% 
Anti-C3c  100 
Anti-C3d  100 
Anti-CRl  0 
Anti-CR2  100 
Anti-C3blNA  100 
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inhibition  did  not  inhibit  the  uptake of small  amounts  of fllH  onto  EC3b.  flirt- 
induced EC3b rosette formation was also completely inhibited with anti-CR2-treated 
and washed Raji cells, whereas there was no inhibition when Raji were treated with 
anti-CR1 both before and during EC3bofllH rosette assay. 
The finding of complete inhibition  by anti-C3c as well as by anti-C3d,  indicated 
that  flirt-induced  EC3b  rosettes  resembled  EC3bi  rosettes  (Table  II).  Thus,  the 
process of rosette formation might involve C3bINA. This hypothesis was confirmed 
by demonstration that anti-C3bINA completely inhibited Raji cell EC3b-fl 1H rosette 
formation, whereas the same antibody had no effect on either EC3bi or EC3d rosette 
formation with Raji cells and did not inhibit  EC3b rosettes with CRl-bearing cells. 
Complete inhibition occurred only when anti-C3bINA was present in the rosette assay 
mixture.  Pretreatment  of Raft cells with anti-C3bINA followed by washing steps to 
remove unbound antibody, produced a lag period in subsequent flirt-induced EC3b 
rosette  formation,  but  did  not  diminish  the  maximum  level  of rosette  formation 
observed  after  60  minutes  (Fig.  2).  These  data  indicated  that  Raji  cells  released 
C3bINA that converted EC3b-fllH to EC3bi, and that these EC3bi and not the EC3b 
were bound subsequently to CR2. 
Synthesis of CgbINA by Lymphocytes.  Raji cells cultured in media supplemented with 
radiolabeled amino acids, were examined by immunoprecipitation for incorporation 
of  radiolabel  into  C3blNA  antigen.  By  immunodiffusion  analysis,  radiolabeled 
C3blNA was detected in both culture supernates and detergent-solubilized cell pellets 
(Fig. 3).  By a  reverse Mancini  radial immunodiffusion assay, it was also shown that 
absorption  of anti-C3blNA  with  Raji cells removed >50% of the antibody activity 
directed to serum C3blNA. 
flirt-induced Release of Lymphocyte CgblNA.  Raji cells were incubated in BDV buffer 
either with or without  30 pg/ml of fllH for 60 min at 37°C, and  then the cell-free 
supernates were harvested after centrifugation  and  tested  for their ability to cleave 
cell bound C3b into C3bi. When the supernate derived from ]31H-treated Raji cells 
was incubated overnight at 37°C with EC3b prepared with all-labeled C3, a portion 
of the bound C3b was converted to C3bi as shown by SDS-PAGE and fluorography 
of the  solubilized  EC3b  cells  (Fig.  4).  Appearance  of the  43,000-dalton  a'-ehain 
fragment after reduction of disulfide bonds is characteristic of bound C3bi (33). C3bi 
formation  by  supernates  of flirt-treated  cells  was  completely  prevented  by  the 
presence of anti-C3blNA (Fig. 4). 
The most sensitive assay for C3blNA was the induction of EC3b rosette formation 
with Raji cells. Studies of EC3bi prepared with increasing amounts of 3H-labeled C3 1634  fllH-INDUCED RELEASE OF C3b  INACTIVATOR 
Fro.  3.  Demonstration  of Raji cell aH-leucine endogenously-labeled  C3blNA by immunodiffusion 
and fluorography. Goat anti-C3bINA  was placed in the outer well and solubilized Raft cells were 
placed in the center well of panel A and culture supernate in the center well of panel B. The 
positions of the radioactive precipitin lines (indicated with arrows) exactly corresponded to the 
position of the amido black-stained serum C3bINA precipitin line. Other outer wells contained 
antibodies specific for human serum proteins other than C3bINA, and  formed only unlabeled 
precipitin lines (anti-IgG  and anti-ceruloplasmin). 
demonstrated that plateau  values for Raji rosette formation could be achieved with 
as few as  1.5  X  103 molecules of bound C3bi per EC3bi. Thus, with the usual EC3b 
that contained  1.5 ×  104 molecules of C3b per cell,  maximum Raji rosette formation 
required cleavage of only  10% of bound C3b to C3bi.  Using this Raji cell assay for 
C3bINA, normal blood and  tonsil  lymphocytes, and  various B  lymphoblastoid cell 
lines  were  analyzed  for  C3bINA  release  after  treatment  with  buffer  either  that 
contained or lacked 30 #g/ml offllH (Tabie IV). flirt-induced C3bINA release was 
detected  with  all  lymphoid cell  types  examined.  In  addition  to  fluid-phase  fllH, 
bovine E coated with fllH (but not with BSA) induced C3bINA release.  Treatment 
of all fl 1  H-induced cell supernates with anti-C3bINA completely blocked their ability 
to generate EC3b rosette formation with Raji cells, confirming the C3bINA specificity 
of this assay with each cell type. Where noted in Table IV, fllH was added to control 
cell-free  supernates  to  assure  that  low  amounts  of C3bINA  were  not  overlooked 
because of missing fllH potentiation of C3bINA activity. 
Sucrose  density-gradient  analysis  of various  purified  fllH  preparations  demon- 
strated that 5%-50% of the fllH was aggregated into hexomers of ~9 ×  105 mol wt, 
whereas  the  remaining fllH  was  monomeric and  1.5  ×  l0  s  mol  wt.  Aggregation 
apparently occurred during concentration of purified fllH by high pressure ultrafil- 
tration,  as fllH  aggregation was undetectable  by gel  filtration  chromatography of 
solubilized  fllH  following polyethylene glycol precipitation.  When  Raji  cells  were 
treated  with  30  #g/ml  of a  fllH  preparation  that  was  estimated  to  be  90-95% 
monomeric fllH and  5-10% hexomeric flirt  by sucrose gradient  analysis, C3bINA 
release was detectable in the cell-free supernate by induction of Raji cell-EC3b rosette 
formation. Monomeric fllH taken directly from sucrose density fractions could not be 
used in rosette assays without prior dialysis, as high sucrose concentrations lysed Raji 
cells.  Dialysis  against  BDV  resulted  in  trace  amounts  of fllH  precipitation,  and 
presumably,  also  some  soluble  fllH  aggregates,  as  30  /zg/ml  of the  dialyzed  and 
centrifuged fllH induced C3bINA release. 
Demonstration offllH Receptors.  Raji cells exhibited a dose-dependent and saturable FIG.  4.  Demonstration  of EC3b  conversion  into  EC3bi  by  cell-free  and  serum-free supernates 
obtained  from flirt-triggered  Raji  cells. Track  A  was overloaded  with  untreated  EC3b[3H]  and 
shows no detectable contaminating C3bi on the EC3b before treatment with  Raji supernatant. In 
track A  the fl-chain of C3b  (75,000 dahons) is just above the position of the BSA marker (68,000 
dahons).  The  higher molecular  weight  bands in  track  A  represent  covalent  complexes of the a' 
chain of C3b and various sheep E  membrane proteins (33).  Track B contained EC3b treated  with 
the supernate of Raji cells that had been incubated with 30 p.g/ml offlltt for 60 rain at 37°C. The 
43,000-dahon fragment of the a'-chain of C3bi appears at the same position as the parallel chicken 
ovalbumin marker and below the intact fl-chain (33).  The larger 68,000-dahon a'-chain fragment 
of C3bi  remains covalently-complexed to  several  different  molecular weight  sheep E  membrane 
proteins and  is represented  by the faint  higher molecular weight  bands positioned above the fl- 
chain. Track C  contained EC3b[3H]  treated with the supernate of Raji cells incubated in flllt-free 
BDV buffer for 60 rain at  37°C. Only trace amounts of the C3bi-specific 43,000 dahon a'-chain 
fragment were observed, indicating only low levels of spontaneous C3blNA release in the absence 
of/~lH-triggering. Track  D  contained EC3b[3H]  treated  with  the cell-free supernate of Raji cells 
incubated with 30/xg/ml of/~lH and goat IgG anti-C3blNA. 
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TABLE IV 
flirt-induced  Release of C3bINA from Normal Lymphocytes and Various Lymphoblastoid Cell Lines as 
Detected by Conversion of Raji Rosette-Negative  EC3b to Raft Rosette-Positive EC3bi 
Cell  Cell treatment 
Raji rosettes 
with EC3b  Addition to  that were  harvested su-  treated with 









Buffer  fllH  15 
fllH  Buffer  85 
flirt and anti-C3blNA  Buffer  0 
Buffer  fllH  10 
fllH  Buffer  90 
fllH and anti-C3blNA  Buffer  0 
Buffer  flirt  0 
flirt  Buffer  85 
fllH and anti-C3blNA  Buffer  0 
fll H-coated E  Buffer  28 
BSA-coated E  Buffer  0 
Buffer  fllH  0 
fllH  Buffer  62 
flirt and anti-C3bINA  Buffer  0 
Buffer  fllH  5 
fllH  Buffer  60 
fllH and anti-C3bINA  Buffer  0 
I 
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FIG. 5.  Demonstration of flirt-specific membrane receptors by assay for binding of all-labeled 
fllH to Ra~,i cells. The total uptake of all-labeled fllH is shown by the top curve (O). Nonspecific 
uptake of  H-labeled fllH was determined with a  1,000-fold molar excess of unlabeled flirt (X). 
Specific uptake offllH (0) was calculated by subtraction of nonspecific  uptake from total uptake, 
uptake of OH-labeled fllH (50% hexomeric) that was inhibitable by excess unlabeled 
fllH  (95%  monomeric)  (Figure 5).  Individual flirt-binding cells were identified by 
immunofluorescence after incubation of cells in unlabeled fllH. Approximately 10- 
15% of Raji cells were stained brightly and an additional 30-40% of Raji cells were 
stained weakly by this technique. Double-label immunofluorescence assay of norma| 
peripheral blood lymphocytes for fllH receptors with fluorescein and for surface Ig JOHN  D.  LAMBRIS,  NORMAN J.  DOBSON,  AND GORDON  D.  ROSS  1637 
with  rhodamine,  demonstrated  that  nearly all  cells  that  bore fllH  receptors  also 
expressed  surface  Ig.  Assay  of fllH  receptors  by  rosette  assay  with  flirt-coated 
erythrocytes  (34)  detected  <10%  as  many  flirt-receptor bearing  cells  as  did  the 
immunofluorescence assay. 
Energy  and  Metal  1on  Requirements.  Raji  cell  flirt-induced  EC3b  rosettes  were 
completely inhibited by the presence of either EDTA or Mg-EGTA. Resuspension of 
EDTA-treated Raji cells in buffer lacking EDTA restored flirt-induced EC3b roset- 
ting. By comparison, EDTA and Mg-EGTA produced very little inhibition of either 
CRl-or  CR2-dependent  rosettes with  EC3b  and  EC3d  respectively. EDTA neither 
inhibited the uptake offllH onto fllH receptors nor inhibited the cleavage of C3b by 
C3blNA.  Sodium azide was also observed to completely inhibit flirt-induced EC3b 
rosette formation, whereas removal of azide restored fll H-induced rosetting capacity. 
Discussion 
The major conclusion derived from these studies is that B lymphocytes and B-type 
lymphoblastoid cell lines express membrane receptors for fll H  that trigger the release 
of endogenous C3blNA.  B cells, exposed to highly purified fllH, converted nearby 
EC3b to EC3bi, and then these EC3bi were subsequently bound to CR2 receptors. 
Synthesis of C3blNA  was  confirmed by lymphocyte incorporation of radiolabeled 
amino acids into C3blNA antigen, and by inhibition of lymphocyte cleavage of C3b 
into C3bi by anti-C3blNA. Little, if any, spontaneous release of C3blNA was detected 
when lymphocytes were incubated in buffer lacking fllH. Lymphocyte receptors for 
flirt were detected by the uptake of 3H-labeled ~IH, and individual B cells with fllH 
receptors were identified by immunofluorescence following treatment of lymphocytes 
with unlabeled fll H. 
In previous studies, complex bound C3 has been shown to bind to B lymphocytes 
by way of two distinct types of membrane C  receptors that are designated CR1 and 
CR2  (35).  Each  of these  two  types  of C  receptors  has  been  isolated  and  specific 
antibodies have been prepared by immunization with the purified receptors. CR1 was 
isolated from erythrocyte membranes and shown to be a 205,000 mol wt single-chain 
glycoprotein (23, 24) that bound to both C3b and C4b, but not to C3bi or C3d. 3 Fab- 
anti-CR1 inhibited EC3b (24) and EAC14b rosettes with all leukocyte types, but had 
no effect on EC3bi or EC3d rosettes (Table II). The finding of inhibition of EC3b- 
CR1 rosettes by Fab-anti-C3c, but not by Fab-anti-C3d (Table II), indicated that the 
binding site for CR~ was in the c region of C3b and not close enough to the d region 
for steric hindrance  by Fab-anti-C3d.  CR2  was  isolated  from spent  media  used  to 
culture Raji cells and was shown to be a  72,000-mol wt single-chain glycoprotein that 
bound to C3bi and C3d, but not to C3b or C4b. 2 Anti-CR2 was shown to be specific 
for a single endogenously 14C-labeled 72,000-dalton protein obtained from an NP-40 
lysate of Raji cells.  Fab-anti-CRz inhibited EC3d rosette formation with all  B-type 
lymphoid cells examined, but had no effect on EC3b or EAC 14b rosette formation 
(Table II). 
Tests of C  receptor reagents for specificity and sensitivity suggested that  lympho- 
cytes might also express a  third type of C3 receptor that was distinct from CR1 and 
CR2, and possibly the same as myeloid cell CRz (35).  EC3bi were apparently bound 
'~ Dobson,  N. J., J.  D.  Lambris, and G.  D.  Ross. Characteristics of isolated  erythrocyte complement 
receptor type one (CRh C4b-C3b receptor)  and CRi-specific antibodies.J. IrnmunoL In press. 1638  fllH-INDUCED  RELEASE OF C3b INACTIVATOR 
to B cells by two different types of receptors. Excess and saturating amounts of F(ab')2- 
anti-CR2 that totally inhibited all EC3d-CR2 rosettes produced only 50-60% inhibi- 
tion of EC3bi rosettes. Further studies will attempt to characterize the specificity of 
lymphocyte CRz more precisely and determine the relationship of lymphocyte CRa to 
myeloid cell CRz. 
CRl  was undetectable  on the surface of Raji  and  Daudi  cells when analyzed by 
three different procedures, including a radioimmune assay with 125I-labeled  Fab-anti- 
CR1. EC3b that contained three times more bound C3b than was required to obtain 
plateau values for CRl-dependent  human E  rosette formation did not  form rosettes 
with  Raji  cells  (Table  I).  Raji  cell-EC3b  rosettes  were  induced,  however,  by  the 
addition  of as  little  as  5  ~g/ml  of purified  /31H  (representing  1%  of plasma filH 
concentration).  Rosette  formation  also  occurred  with  preformed  EC3b-filH  com- 
plexes, whereas removal of all bound/~ 1  H from EC3b completely inhibited subsequent 
rosette formation. 
/31H-induced  EC3b rosettes with Raji cells were bound to CR2 and not to CR1 or 
to ~IH  receptors.  Pretreatment  of Raji cells with F(ab')z-anti-CR2 totally inhibited 
flirt-induced EC3b rosettes, whereas the presence of Fab-anti-CR1 or concentrations 
of fluid-phase/~IH _<5.5 mg/ml had no effect on subsequent/31H-induced  rosettes. 
Rosette formation was also inhibited completely by the presence of either Fab-anti- 
C3c  or  Fab-anti-C3d.  However,  pretreatment  of  EC3b  with  either  of  these  two 
antibodies  had  no effect on/31H-induced  rosettes.  By comparison, pretreatment  of 
EC3b with Fab-anti-C3c completely inhibited CRvdependent rosettes, and pretreat- 
ment  of EC3bi  or  EC3d  with  Fab-anti-C3d  completely  inhibited  CR2-dependent 
rosettes (Table II). These observations indicated that the C3 determinants that bound 
to  Raji  cells  were  not  exposed  on  EC3b  but  were  uncovered  by  Raji  cells  in  the 
presence  of/~IH.  Furthermore,  the  inhibition  by anti-C3c  as  well  as  by anti-C3d 
suggested that the specificity of~ 1H-induced EC3b rosette formation resembled that 
observed with  EC3bi  rosette formation.  Control  studies with 3H-labeled BIH dem- 
onstrated that the anti-C3c and anti-C3d used for rosette inhibition did not block the 
uptake  of/~IH onto  EC3b.  These  results  indicated  that  Raji  cells  might  release  a 
C3blNA-like enzyme that converted EC3b  into EC3bi  in the presence of flirt, and 
that  these EC3bi  were bound  subsequently to Raji  cell-CR2 forming rosettes.  This 
hypothesis  was  confirmed  by  the  finding  that  /31H-induced  EC3b  rosettes  were 
completely inhibited  by the presence of anti-C3blNA. Thus, Raji cells did not bind 
EC3b-/31H to either CR2 (36)  or to/~IH receptors (34), but instead converted EC3b- 
filH  into  EC3bi  that  bound  to CR2.  The finding  that/~lH-induced  EC3b  rosettes 
were completely inhibited  by anti-CR2, whereas EC3bi  rosettes were inhibited  only 
50-60%  by anti-CR2 suggests that only small amounts of C3bi were formed on the 
EC3b and that this C3bi was bound preferentially to CR2 rather than to CR3. The 
finding of complete inhibition  by anti-C3c suggests that  little,  if any, of the bound 
C3bi was fully degraded to C3d, as anti-C3c had no effect on EC3d rosettes  (Table 
II). 
Lymphocyte synthesis of C3bINA was confirmed by immunodiffusion and fluorog- 
raphy  analysis  of spent  media  and  solubilized  Raji  cells  obtained  from overnight 
culture in radiolabeled amino acids. Anti-C3bINA formed a single precipitin line of 
identity with serum C3bINA and a radiolabeled C3bINA protein synthesized by Raji 
cells.  Identity of lymphocyte C3bINA  with  serum  C3bINA  was  also  indicated  by JOHN D.  LAMBRIS, NORMAN J.  DOBSON, AND GORDON D.  ROSS  1639 
antibody absorption experiments. Absorption of anti-C3blNA with Raji cells removed 
>50% of the antibody directed to human serum C3bINA. In addition to detection of 
the incorporation of labeled amino acids into C3bINA antigen, C3bINA activity was 
demonstrated in serum-free lymphocyte supernates by conversion of EC3b to EC3bi 
detected by SDS-PAGE and by conversion of Raji-rosette-negative EC3b into Raji- 
rosette-positive EC3bi.  Each assay was shown to be specific for C3bINA by parallel 
controls that demonstrated that anti-C3bINA completely inhibited the activity meas- 
ured. 
C3bINA  was  released  from  lymphocytes  in  response  to  /~IH,  and  very  little 
spontaneous release of C3bINA occurred in the absence of ~ 1H. Cell-free supernates 
from Raji cells treated with/~IH converted EC3b to EC3bi as determined by SDS- 
PAGE  analysis.  Very  little  C3bi  was  generated  on  EC3b  treated  with  cell-free 
supernates obtained from Raji cells incubated in/~lH-free buffer. 
Normal lymphocytes from blood and tonsils also released C3bINA after exposure 
to/~ 1H. However, it was only possible to measure CR2-specific/~ 1  H-induced EC3b 
rosettes  with  normal  lymphocytes  that  had  been  pretreated  with  Fab'-anti-CRa, 
because untreated normal lymphocytes bound EC3b to CRx in the absence of/~IH. 
After Fab'-anti-CR1 pretreatment, normal lymphocyte ~lH-induced CR2-dependent 
rosettes with EC3b were nearly equivalent to EC3bi rosettes (data not shown)./~IH- 
induced normal lymphocyte release of C3bINA was more easily measured by testing 
cell-free supernates of~lH-treated cells by a  Raji cell assay for conversion of rosette- 
negative EC3b into rosette-positive EC3bi (Table IV). With both normal lymphocytes 
and cells from two other B lymphoblastoid lines, C3bINA release was stimulated by 
the presence of/~lH, and little C3bINA release occurred spontaneously in the absence 
of/~IH. 
B  lymphocytes expressed ~lH-specific  receptors  of relatively  low  affinity. /~IH 
receptors  appeared  to  be  saturable  and  reversible,  however,  this  was  difficult  to 
confirm with the [3H]/~IH used for this study as it contained ~50% hexomeric/~IH. 
Scatchard plot analysis of Raji cell ~ 1H uptake demonstrated the presence of at least 
two different binding species of this [3H]/~IH preparation, and from this it is assumed 
that  the hexomeric [3H]/~IH had  a  higher affinity for/~IH receptors than  did  the 
monomeric  [3H]~IH  in  the  labeled/~IH  preparation  (Scatchard  plot  not  shown). 
Thus far it has been difficult to isolate monomeric/~ 1H t hat is totally free of hexomeric 
/~IH. By criteria other than Scatchard analysis, [3H]/~IH did appear to have a much 
lower affinity for Raji cell ~IH receptors that  it had for EC3b.  Elution of [3H]/~IH 
from EC3b-/~IH required six washes with warm high-ionic strength buffer, whereas 
[3H]/~IH was easily eluted from Raji cells by two washes with ice-cold isotonic buffer. 
fllH receptors were also difficult to detect by rosette assay with/~ 1H-coated erythro- 
cytes  (34).  Individual cells with/~IH  receptors were more easily identified with an 
immunofluorescence assay for the uptake of unlabeled ~IH. Double-label studies of 
normal lymphocytes indicated that/~1H receptors were expressed only on B cells. 
fllH  receptors  presumably  have  to  be  crosslinked  on  the  cell  surface  to  trigger 
C3bINA  release.  However, at  this  time  it  is  unclear  whether  this  requires  either 
aggregated or complex-bound/~ 1H. Treatment of lymphocytes with 30/~g/ml of/~ 1H 
that  was  ~90%  monomeric  and  10%  hexomeric induced  C3bINA  release.  In  the 
future, attempts will be made to isolate 100% monomeric ~ 1  H, because it is presumed 
that  plasma/~IH  is  monomeric and  does not  trigger/~IH  receptors. Alternatively, 1640  fllH-INDUCED RELEASE OF C3b INACTIVATOR 
fllH  isolation  procedures may generate an  activated  form of fllH  similar  to  that 
which has been described for P  (37). 
fllH  receptor-mediated release of C3bINA  may involve a  calcium-  and  energy- 
dependent transport of C3bINA through the lymphocyte membrane. EDTA did not 
inhibit  the  uptake  of fllH  onto lymphocyte receptors, but  flirt-induced  C3bINA 
release was inhibited completely in the presence of either EDTA, magnesium-EGTA, 
or sodium azide.  Because the C3bINA releasing activity of EDTA-treated cells was 
restored by washing with EDTA-free buffer, it is possible that intracellular stores of 
calcium  restored  membrane  calcium  following  removal  of EDTA.  Alternatively, 
EDTA and  EGTA may inhibit  directly by binding to some membrane constituent 
required for release of C3bINA. 
The immunologic significance offl 1  H-induced release of C3bINA from lymphocytes 
remains to be established by future investigation. Because fllH and C3bINA are both 
synthesized and released by lymphocytes (38), it is possible that these two components 
may play some role in antigen recognition and the immune response. In this regard 
it should be noted that C3bINA does not cleave all bound C3b molecules with equal 
efficiency and that C3b bound to alternative pathway-activating surfaces is particu- 
larly resistent to C3bINA. This increased resistence of C3b to C3bINA is determined 
by the relative binding affinity of fllH for C3b, which is regulated by the physico- 
chemical properties of the surface to which C3b is bound (8, 9). Many different strains 
of bacteria  and  yeast,  as  well  as  certain  human  tumor  cells,  have  outer  wall  or 
membrane  structures  that  function  as  activating  surfaces  for  the  C  alternative 
pathway. When C3b is bound to an alternative pathway-activating surface, fllH has 
a reduced affinity for C3b that results in diminished C3b cleavage by C3bINA. This 
allows the uncleaved C3b to become a site for assembly of  the amplification convertase, 
C3b,Bb,P.  By contrast, when C3b  is bound to normal  tissue surfaces, it has a  high 
affinity for fllH and  is rapidly degraded by C3bINA to C3bi. Thus, the plasma C 
system has this mechanism of distinguishing self from nonself, whereby C3b deposited 
onto self surfaces is degraded into C3bi, whereas C3b deposited onto non-self surfaces 
is allowed to form the amplification convertase that activates the cytolytic terminal 
C components. Cells or other C-fixing complexes that are not lysed by this mechanism 
would then presumably circulate with either C3bi (self) or C3b,Bb,P (non-self) bound 
to exposed surfaces.  Recent studies have suggested that cells of the immune system 
may have membrane recognition systems capable of responding to C3b,Bb,P-coated 
non-self substances,  and  likewise  also  possess  a  control  mechanism  to  prevent  a 
response to C3bi-coated self  substances. Macrophages have been shown to be activated 
by  factor  Bb  (39)  through  cleavage of their  surface-bound  C5  (40).  In  addition, 
macrophages  synthesize and  release fllH  and  C3bINA  (4)  that  might  potentially 
degrade the C3b,Bb,P enzyme on normal tissue, thus limiting cell activation to non- 
self surfaces. Preliminary evidence has now been obtained that  B lymphocytes may 
possess a  similar membrane recognition system to distinguish  C-activating surfaces 
(38). Not only do lymphocytes synthesize C3bINA, but they also synthesize fllH (38), 
factor B, and  P  (5), and express C5 as an exposed membrane-bound component (3, 
38). Cleavage of this surface-bound C5 by exposure to EAC14°xY23b  or EC3b,Bb,P 
leads to release of both flirt and C3bINA that convert EC3b to EC3bi (38).  Present 
evidence indicates  that  this  surface C5-mediated  mechanism  of C3bINA  release  is 
probably independent of the fllH receptor-mediated mechanism of C3bINA release. JOHN D. LAMBRIS, NORMAN J.  DOBSON, AND GORDON D.  ROSS  1641 
The same  magnesium  EGTA buffer that  totally inhibited fllH  receptor-mediated 
C3blNA release had no effect on C5-mediated C3blNA release. Sundsmo  (3), who 
first  described  lymphocyte surface  C5,  has  recently reported  that  F(ab')2  anti-C5 
induced B cell blastogenesis, whereas Fab-anti-C5 inhibited mixed lymphocyte reac- 
tions (41). The relationship of this surface C5-dependent blastogenic response to CS- 
mediated release of/~lH and C3blNA is presently being investigated. 
The possible involvement of the C system in the various stages of antigen trapping, 
recognition,  and  lymphocyte  activation  has  been  suggested  by  several  previous 
investigators (42-44). In particular, a role for endogenous factor B and C3blNA was 
hypothesized by Hartman and Bokisch (45, 46) before the synthesis of these compo- 
nents by lymphocytes had been demonstrated. Future studies will be aimed at further 
characterizing the components and reactions of the lymphocyte and macrophage C 
system and how this system relates to the overall functions of these cells in the host 
defense mechanism. 
Summary 
Human bone marrow-derived lymphocytes and cells from B lymphoblastoid lines 
were shown  to  have specific membrane receptors  for ~IH  globulin.  Lymphocytes 
responded to the presence of/31H by releasing endogenously-synthesized C3b-inacti- 
vator. Very little spontaneous release of C3b-inactivator occurred in the absence of 
/31H.  /31H-treated  lymphocytes that  either  lacked  complement  receptor  type one 
(CR1,  the C4b-C3b  receptor) or had their CR1 blocked with Fab'-anti-CR1  formed 
rosettes with  C3b-coated  sheep  erythrocytes (EC3b)  by adherence  to  complement 
receptor type two (CR2, the C3d-C3bi receptor). The mechanism of this ~lH-induced 
EC3b rosette formation was shown to involve the release of lymphocyte C3b-inacti- 
vator that cleaved bound C3b into C3bi forming EC3bi. This lymphocyte-generated 
EC3bi  then  bound  to  CR2,  forming  rosettes.  ,81H-induced  EC3b  rosettes  were 
completely inhibited by the presence of either anti-C3b-inactivator, F(ab')2-anti-CR2, 
Fab-anti-C3c, or Fab-anti-C3d,  but were unaffected by the presence of fluid-phase 
concentrations of~lH up to 5.5 mg/ml or Fab'-anti-CR1. Analysis by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis and fluorography demonstrated that cell- 
free supernates of ,81H-treated lymphocytes cleaved 3H-labeled C3b on EC3b into 
C3bi.  Inhibition studies with chelating agents and sodium azide suggested that  the 
release of C3b inactivator might involve a calcium and energy-dependent transport 
of this enzyme across  the membranes of/~lH-triggered cells.  Because plasma ]~IH 
and  C3b-inactivator  are  known  to  have  important  functions in  the  distinction  of 
alternative pathway-activating substances from normal tissue, it is possible that  this 
/~ 1H receptor-C3b-inactivator releasing system in lymphocytes may have an analogous 
function. 
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